{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:25:00Z","timestamp":1790115900406,"version":"4.0.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.hfc.2024.09.003","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T14:18:46Z","timestamp":1729261126000},"page":"e1-e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S","title":["Cardiac Amyloidosis"],"prefix":"10.1016","volume":"20","author":[{"given":"Giorgia","family":"Panichella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Arzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Giannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.hfc.2024.09.003_bib1","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3390\/biomedicines10071566","article-title":"Re-definition of the epidemiology of cardiac amyloidosis","volume":"10","author":"Rossi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.hfc.2024.09.003_bib34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European society of cardiology working group on myocardial and pericardial diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/978-3-319-67144-4_30","article-title":"The European Union policy in the field of rare diseases","volume":"1031","author":"Moliner","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.hfc.2024.09.003_bib36","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. a systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"Supplement_1","key":"10.1016\/j.hfc.2024.09.003_bib2","doi-asserted-by":"crossref","first-page":"ehab724","DOI":"10.1093\/eurheartj\/ehab724.3131","article-title":"Epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) in France, a study based on the systeme national des donnees de sante (SNDS) the French nationwide claims database","volume":"42","author":"Damy","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2024.09.003_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijcard.2023.03.063","article-title":"Prevalence of transthyretin-related amyloidosis in Tuscany: data from the regional population-based registry","volume":"382","author":"Cappelli","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13506129.2016.1207626","article-title":"Incidence rate of amyloidosis in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort","volume":"23","author":"Aguirre","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.hfc.2024.09.003_bib5","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ehf2.13961","article-title":"Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic Countries","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib7","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2024.09.003_bib8","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2024.09.003_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12265-019-09895-0","article-title":"Prevalence of cardiac amyloidosis in patients with carpal tunnel syndrome","volume":"12","author":"Zegri-Reiriz","year":"2019","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.hfc.2024.09.003_bib10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijcard.2020.12.044","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study","volume":"329","author":"Vianello","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib11","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2024.09.003_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.hfc.2024.09.003_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13506129.2022.2026323","article-title":"Epidemiology of hereditary transthyretin amyloidosis in the northernmost region of Sweden: a retrospective cohort study","volume":"29","author":"Mejia Baranda","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.hfc.2024.09.003_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/13506129.2020.1794807","article-title":"ATTRv Amyloidosis Italian Registry: clinical and epidemiological data","volume":"27","author":"Russo","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.hfc.2024.09.003_bib16","doi-asserted-by":"crossref","first-page":"E200013","DOI":"10.1212\/NXG.0000000000200013","article-title":"High hereditary transthyretin-related amyloidosis prevalence in crete: genetic heterogeneity and distinct phenotypes","volume":"8","author":"Tzagournissakis","year":"2022","journal-title":"Neurol Gen"},{"key":"10.1016\/j.hfc.2024.09.003_bib17","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.cardfail.2017.07.207","article-title":"Estimating population-level prevalence of wild-type and variant transthyretin amyloid cardiomyopathy","volume":"23","author":"Grogan","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40119-019-0142-5","article-title":"Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan","volume":"8","author":"Winburn","year":"2019","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.hfc.2024.09.003_bib19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jchf.2021.05.005","article-title":"Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS","volume":"9","author":"Caponetti","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in olmsted county, Minnesota, 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proceed"},{"key":"10.1016\/j.hfc.2024.09.003_bib21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using us claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.hfc.2024.09.003_bib22","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/1471-2458-12-974","article-title":"Incidence and survival in non-hereditary amyloidosis in Sweden","volume":"12","author":"Hemminki","year":"2012","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.hfc.2024.09.003_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2024.09.003_bib24","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1182\/blood.V128.22.4448.4448","article-title":"Improved survival in AL amyloidosis: a population-based study on 1,430 patients diagnosed in Sweden 1995-2013","volume":"128","author":"Weiss","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2024.09.003_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2021.12.048","article-title":"Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis","volume":"351","author":"Zampieri","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib27","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10554-016-0915-z","article-title":"Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy","volume":"32","author":"Bennani Smires","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.hfc.2024.09.003_bib28","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/ejhf.1756","article-title":"Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome","volume":"22","author":"Nitsche","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib29","doi-asserted-by":"crossref","first-page":"749523","DOI":"10.3389\/fcvm.2021.749523","article-title":"Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination","volume":"8","author":"Porcari","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.hfc.2024.09.003_bib30","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and survival trends in amyloidosis, 1987-2019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2024.09.003_bib31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S39981","article-title":"Systemic AA amyloidosis: epidemiology, diagnosis, and management","volume":"6","author":"Real De As\u00faa","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/13506129.2016.1145110","article-title":"Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico","volume":"23","author":"Larsen","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.hfc.2024.09.003_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.kint.2018.10.036","article-title":"Predilution online hemodiafiltration is associated with improved survival compared with hemodialysis","volume":"95","author":"Kikuchi","year":"2019","journal-title":"Kidn Int"},{"key":"10.1016\/j.hfc.2024.09.003_bib37","first-page":"17","article-title":"ATTR epidemiology, genetics, and prognostic factors","volume":"18","author":"Obi","year":"2022","journal-title":"Meth Debak Cardiovasc J"},{"key":"10.1016\/j.hfc.2024.09.003_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects: jacc: cardiooncology State-Of-The-Art Review","volume":"4","author":"Wechalekar","year":"2022","journal-title":"JACC Cardiooncol"},{"key":"10.1016\/j.hfc.2024.09.003_bib39","first-page":"11","article-title":"Clinical aspects of systemic amyloid diseases","volume":"1753","author":"Obici","year":"2005","journal-title":"Bioch Biophys Acta"},{"key":"10.1016\/j.hfc.2024.09.003_bib40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/000456329803500607","article-title":"Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum","volume":"35","author":"Ledue","year":"1998","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.hfc.2024.09.003_bib41","doi-asserted-by":"crossref","first-page":"1158083","DOI":"10.3389\/fimmu.2023.1158083","article-title":"The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: from mechanisms to therapeutic potential","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.hfc.2024.09.003_bib42","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2024.09.003_bib43","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"JACC Cardiovasc Imag"},{"key":"10.1016\/j.hfc.2024.09.003_bib45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","article-title":"Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population","volume":"270","author":"Mohamed-Salem","year":"2018","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2024.09.003_bib46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10741-023-10339-w","article-title":"Sex differences in transthyretin cardiac amyloidosis","volume":"29","author":"Aimo","year":"2024","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.hfc.2024.09.003_bib47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40119-022-00265-7","article-title":"Sex differences in wild-type transthyretin amyloidosis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"11","author":"Campbell","year":"2022","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.hfc.2024.09.003_bib48","first-page":"50","article-title":"Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy","volume":"79","author":"Takashio","year":"2022","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib49","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.2824","article-title":"Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis","volume":"25","author":"Aimo","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib50","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1093\/eurjpc\/zwab127","article-title":"A\u00a0national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the Ac-Tive Study","volume":"29","author":"Merlo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib51","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from phase 2 of the Ac-Tive Study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib52","first-page":"2273","article-title":"Estimating the prevalence of cardiac amyloidosis in old patients with heart failure-barriers and opportunities for improvement: the PREVAMIC study","volume":"12","author":"Ruiz-Hueso","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.hfc.2024.09.003_bib53","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib54","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ehf2.13110","article-title":"Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic","volume":"8","author":"Lindmark","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib55","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"Abouezzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib56","doi-asserted-by":"crossref","first-page":"858281","DOI":"10.3389\/fmed.2022.858281","article-title":"Red flags, prognostic impact, and management of patients with cardiac amyloidosis and aortic valve stenosis: a systematic review and meta-analysis","volume":"9","author":"Myasoedova","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.hfc.2024.09.003_bib57","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","article-title":"Global epidemiology of amyloid light-chain amyloidosis","volume":"17","author":"Kumar","year":"2022","journal-title":"Orph J Rare Dis"},{"key":"10.1016\/j.hfc.2024.09.003_bib58","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2024.09.003_bib59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12872-021-01856-3","article-title":"Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-d speckle tracking echocardiography parameters","volume":"21","author":"Lei","year":"2021","journal-title":"BMC Cardiovasc Dis"},{"key":"10.1016\/j.hfc.2024.09.003_bib60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijcard.2019.07.051","article-title":"Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy","volume":"300","author":"Maurizi","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib61","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2024.09.003_bib62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.revmed.2022.12.004","article-title":"French practical guidelines for the diagnosis and management of AA amyloidosis","volume":"44","author":"Georgin-Lavialle","year":"2023","journal-title":"Rev Med Int"},{"key":"10.1016\/j.hfc.2024.09.003_bib63","doi-asserted-by":"crossref","first-page":"757642","DOI":"10.3389\/fcvm.2021.757642","article-title":"Diagnosis of cardiac involvement in amyloid a amyloidosis by cardiovascular magnetic resonance imaging","volume":"8","author":"Chamling","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.hfc.2024.09.003_bib64","doi-asserted-by":"crossref","first-page":"107375","DOI":"10.1016\/j.carpath.2021.107375","article-title":"Clinically occult amyloidosis derived from leukocyte chemotactic factor 2 (ALECT 2) with cardiac involvement complicating renal transplantation: case report and literature review","volume":"55","author":"Eletta","year":"2021","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.hfc.2024.09.003_bib65","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.carpath.2019.05.002","article-title":"The pathology and changing epidemiology of dialysis-related cardiac beta-2 microglobulin amyloidosis","volume":"42","author":"Morris","year":"2019","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.hfc.2024.09.003_bib66","unstructured":"Sekijima Y. Hereditary transthyretin amyloidosis, 2001, Genereviews\u00ae, [Updated 2021 Jun 17]. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1194\/."},{"key":"10.1016\/j.hfc.2024.09.003_bib67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.hfc.2024.09.003_bib68","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajmg.1320600606","article-title":"Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in p\u00f3voa do varzim and vila do conde (North of Portugal)","volume":"60","author":"Sousa","year":"1995","journal-title":"Am J Med Gen"},{"key":"10.1016\/j.hfc.2024.09.003_bib69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2008.02.019","article-title":"Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus","volume":"270","author":"Kato-Motozaki","year":"2008","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.hfc.2024.09.003_bib70","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10741-021-10098-6","article-title":"Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review","volume":"27","author":"Goyal","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.hfc.2024.09.003_bib71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.hfc.2024.09.003_bib72","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2350-14-88","article-title":"Incidence of hereditary amyloidosis and autoinflammatory diseases in Sweden: endemic and imported diseases","volume":"14","author":"Hemminki","year":"2013","journal-title":"BMC Med Gen"},{"key":"10.1016\/j.hfc.2024.09.003_bib73","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hfc.2024.09.003_bib74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000490553","article-title":"Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a nationwide study","volume":"51","author":"In\u00eas","year":"2018","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.hfc.2024.09.003_bib75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal","volume":"35","author":"Concei\u00e7\u00e3o","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.hfc.2024.09.003_bib76","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40120-021-00258-z","article-title":"Characteristics of patients with late- vs. early-onset Val30met transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (THAOS)","volume":"10","author":"Waddington-Cruz","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.hfc.2024.09.003_bib77","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/ejhf.1285","article-title":"Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure","volume":"20","author":"Gagliardi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental western europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"43","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2024.09.003_bib79","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","article-title":"Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges","volume":"26","author":"Bruno","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.hfc.2024.09.003_bib80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cardfail.2020.08.007","article-title":"Sex differences in the phenotype of transthyretin cardiac amyloidosis due to Val122ile mutation: insights from noninvasive pressure-volume analysis","volume":"27","author":"Batra","year":"2021","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib81","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib82","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ejhf.2658","article-title":"Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy","volume":"24","author":"Maestro-Benedicto","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2024.09.003_bib83","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:54:43Z","timestamp":1750852483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713624000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1551713624000801"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2024.09.003","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}